Phio Pharmaceuticals Corp. 8-K Filing
Ticker: PHIO · Form: 8-K · Filed: Nov 25, 2025 · CIK: 1533040
| Field | Detail |
|---|---|
| Company | Phio Pharmaceuticals Corp. (PHIO) |
| Form Type | 8-K |
| Filed Date | Nov 25, 2025 |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Phio Pharmaceuticals Corp. (ticker: PHIO) to the SEC on Nov 25, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (h registered: Common Stock , par value $0.0001 per share PHIO The Nasdaq Capital M).
How long is this filing?
Phio Pharmaceuticals Corp.'s 8-K filing is 1 pages with approximately 437 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 437 words · 2 min read · ~1 pages · Grade level 9.4 · Accepted 2025-11-25 16:12:46
Key Financial Figures
- $0.0001 — h registered: Common Stock , par value $0.0001 per share PHIO The Nasdaq Capital M
Filing Documents
- phio20251121_8k.htm (8-K) — 23KB
- ex_891847.htm (EX-99.1) — 10KB
- logo.jpg (GRAPHIC) — 7KB
- 0001437749-25-036329.txt ( ) — 173KB
- phio-20251125.xsd (EX-101.SCH) — 3KB
- phio-20251125_def.xml (EX-101.DEF) — 12KB
- phio-20251125_lab.xml (EX-101.LAB) — 15KB
- phio-20251125_pre.xml (EX-101.PRE) — 12KB
- phio20251121_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On November 25, 2025, the Company issued a press release announcing the completion of enrollment in its ongoing Phase 1b clinical trial (NCT 06014086) of INTASYL siRNA Lead Compound PH-762. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on November 25, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHIO PHARMACEUTICALS CORP. Date: November 25, 2025 By: /s/ Robert J. Bitterman Robert J. Bitterman President & Chief Executive Officer 3